Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study.

Further research is needed to better characterize the relative importance of different risk factors on outcomes in men vs women and to determine whether gender differences exist in patients treated with non-vitamin K antagonist oral anticoagulants.